logging in or signing up SEMINAR- Bioavailability drmayur2511 Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 344 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: July 18, 2011 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript SEMINAR: SEMINAR BIOAVAILABILITY Dr. Mayur M. Maybhate JR-1, Dept. of Pharmacology IGGMC, Nagpur.Introduction and History: Introduction and History Phenytoin tragedy – Inert diluent Calcium sulphate was substituted by Lactose.Definition: Definition Rate and extent of drug from a dosage form or the fraction of drug that reaches the site of action.Slide 4: Rate and extent of therapeutic moiety in form of parent drug; active metabolite; or active moiety of prodrug from administered dosage form appearing in systemic circulation.Calculation of Bioavailability: Calculation of BioavailabilityTerminologies in Bioavailability: Terminologies in Bioavailability Absolute Bioavailability Denoted by ‘F’. Ranges from 0-1. Expressed as µg-hr/ml. F = AUC ev/AUC ivSlide 7: Route Bioavailability Remark 1) Intravenous 100% Most rapid 2) Intramuscular 75-100% Large volumes needed, Painful 3) Subcutaneous 75-100% Smaller volumes than IM, Often painful 4) Oral 5- < 100% Most convenient, First pass effect significant 5) Rectal 30- < 100% Less first pass effect than oral 6) Inhalational 5- < 100% Very rapid onset 7) Transdermal 80-100% Slow onsetSlide 8: Relative Bioavailability Bioavailability of a drug product as compared to another dosage form or products of same drug given in same dose. F = AUC a/ AUC bSlide 9: Bioequivalence Two drug products are said to be equivalent if rate and extent of their bioavailability is not significantly different under similar test conditions.Slide 10: Clinical Equivalence Therapeutic Equivalence Chemical EquivalenceSlide 11: Disintegration of drug Dissolution of drugSlide 12: Tab/Cap. disintegration Granules disintegration Fine particles dissolution dissolution dissolution Drug in solution absorption Drug in blood, fluids, tissuesFactors affecting Bioavailability: Factors affecting Bioavailability Dosage form related Patient relatedDosage form related factors: Dosage form related factors 1) Physiochemical properties of drug a) Physical state – Solution>Suspension>Capsule>Tablet>Coated TabSlide 15: b) Lipid or Water solubility c) Particle sizeSlide 16: d) Crystal form – e.g. Amorphous Chloramphenicol > Crystalline Chloramphenicol.Slide 17: e) Degree of hydration of crystal – e.g. Anhydrous Ampicillin > Trihydrate form f) Salt form – e.g. Pot.Peni.V > Cal.Peni.V > Peni.VSlide 18: g) Surfactant Better contact of drug solution with cell membrane due to spreading effect.Slide 19: 2) Formulation and manufacturing factors A) Disintegrating agents – a) Agents which swells with moisture e.g. Starch b) Agents which melts at body temp. e.g. Cocoa butter c) Agents which effervesce with moisture e.g. Na2CO3 and tartaric acidSlide 20: B) Amount of lubricant C) Special coatings D) Compression forcePatient related factors: Patient related factors 1) Variation in pH Acidic drugs- stomach Basic drugs - IntestineSlide 22: 2) Gastric emptying rate Factor Effect 1) Increased Viscosity of stomach content Decreased 2) Stress, anxiety Decreased 3) exercise Decreased 4) Fatty meal Decreased 5) Increased pH Decreased pH Increased Decreased 6) Gastric ulcers Chrohn’s disease Hyperthyroidism Decreased Decreased Increased 7) Atropine Metoclopramide Decreased IncreasedSlide 23: 3) First pass metabolism Low Intermediate High- not given orally High- oral dose high Phenobarbitone Aspirin Lignocaine Pethidine Tolbutamide Quinidine Isoprenaline Propranalol Theophylline Pentazocin Hydrocortisone Verapamil phenylbutazone Metoprolol Morphine NortryptilineSlide 24: 4) Age, Sex, Weight 5) Diseased State -GI diseases - Liver diseases - CHFSlide 25: 5) Interactions with other substances a) Food Reduced Delayed Increased Aspirin Acetaminophen Chloroquine Ampicillin Digoxin Mefloquine Atenolol Frusemide Halofantrine Captopril Diclofenac GriseofulvinSlide 26: b) Drugs 1) Direct - Chelation of tetracyclines by metal ions in antacids -Adsorbtion of digoxin by cholestramine - Vit C increases absorption of iron 2 ) Indirect- Increased acetaminophen absoption due to metoclopramide.Measurement of Bioavailability: Measurement of Bioavailability Blood level data Urinary data Clinical data Pharmacological dataMethods for assessment of bioavailability: Methods for assessment of bioavailability Sequence of events Method Example 1) Drug liberation and dissolution Dissolution rate In Vitro; Water, Buffer, Gastric fluid 2) Free drug in systemic circulation Blood level Peak level ( Cmax ) Time to peak ( Tmax ) AUC In vivo; Blood, Serum, Plasma 3) Pharmacological effect Onset of effect Duration of effect Intensity of effect In vivo; Measurement of response (BP, BSL) 4) Clinical response Observed clinical success/failure In vivo; evaluation of clinical response. 5) Elimination Amount of drug excreted In vivo; Urine.Study Design of Bioavailability: Study Design of Bioavailability Reference standard a) New formulation – Approved drug in market b) Controlled Release c) Combination product – Approved combination or single drug productSlide 30: Inclusion and exclusion criteria Sample size Period of trialSlide 31: Fasting/ fed condition Single Vs multiple dose method studies: Choice of parameters a) Peak height (Cmax) b) Time for peak concentration (Tmax) c) Area under curveSlide 33: AUC can be determined by – a) Using Planimeter b) Cut and Weight method c) Trapezoidal ruleConclusion: ConclusionReferences: References Iain L.O. Bruxton,Pharmacokinetics and Pharmacodynamics, Goodman and Gilmans ,Pharmacological basis of therapeutics;11;4-7;2005. H. Rang and M. Dale , Absoption and distribution of drugs; Pharmacology; 5,91-104Slide 36: Tripathi K.D .,Phamacokinetic- Membrane transport, absoption and distribution of drugs,Essentials of Medical Pharmacology; 6;15-8;2008. R.S.Satoskar ,General considerations and pharmacokinetics,Pharmacology and pharmacotherapeutics;21;9-13;2009Slide 37: HL Sharma, KK Sharma , Phamacokinetics,Principles of Pharmacology;1;29-34;2008 Harbert M.,Pharmacokinetics, Katzung B.G., Basis of clinical pharmacology;11;11-15;2009Slide 38: Shargel, L.; Yu, A.B.; Applied biopharmaceutics & pharmacokinetics ;New York: McGraw-Hill;4;21-34,1999.Slide 39: Thank You !!! You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.